Temeck B K, Bachenheimer L C, Katz N M, Coughlin S S, Wallace R B
Department of Surgery, Georgetown University School of Medicine, Washington, DC 20007.
South Med J. 1994 Jun;87(6):611-5. doi: 10.1097/00007611-199406000-00006.
Use of desmopressin acetate (DDAVP) for patients having cardiac surgery is controversial. We did a double-blind, randomized study of 83 patients having cardiac operations at Georgetown University Hospital. The effect of DDAVP on bleeding as compared to placebo was evaluated by blood loss, replacement volume, and laboratory tests. There were no significant differences in baseline and intraoperative data between the DDAVP (n = 40) and placebo (n = 43) groups. Total drainage for the first 24 postoperative hours was 1,214 mL (+/- 78) for the DDAVP group and 1,386 mL (+/- 116) for the placebo group (not significant). There were no significant differences in replacement therapy. In this study, administration of DDAVP did not decrease bleeding.
对接受心脏手术的患者使用醋酸去氨加压素（DDAVP）存在争议。我们在乔治敦大学医院对83例接受心脏手术的患者进行了一项双盲随机研究。通过失血量、补液量和实验室检查评估了DDAVP与安慰剂相比对出血的影响。DDAVP组（n = 40）和安慰剂组（n = 43）之间的基线和术中数据无显著差异。DDAVP组术后24小时的总引流量为1214 mL（±78），安慰剂组为1386 mL（±116）（无显著差异）。替代治疗方面无显著差异。在本研究中，使用DDAVP并未减少出血。
